Hanmi Pharm "Candidate Substance for Short Bowel Syndrome Treatment Shows Potential for Indication Expansion"

"Confirmation of Possibility for Graft-versus-Host Disease Treatment"
Presented at the European Society for Clinical Nutrition and Metabolism

Hanmi Pharmaceutical has suggested the possibility of developing a treatment for graft-versus-host disease (GVHD), another rare disease, using its short bowel syndrome treatment, which is being developed as the world's first once-monthly formulation.

Notice regarding the presentation content of 'ESPEN Congress 2023' posted on Hanmi Pharmaceutical's English website.
[Image provided by Hanmi Pharmaceutical]

Hanmi Pharmaceutical announced on the 14th that it presented two research results on the short bowel syndrome treatment 'LAPS GLP-2 analog (HM15912)' in poster sessions at the European Society for Clinical Nutrition and Metabolism (ESPEN Congress 2023), held in Lyon, France, from the 11th to the 14th (local time).

In the presentation, Hanmi Pharmaceutical proposed the therapeutic potential of HM15912 for GVHD based on its efficacy in promoting small intestine growth and alleviating intestinal inflammation. GVHD is a disease in which transfused lymphocytes attack the body of patients with weakened immune function during bone marrow transplantation, causing complications with a very high mortality rate. Currently, steroids and steroid-immunosuppressant combination therapies are used as standard treatments, but Hanmi Pharmaceutical explained that there are limitations in treatment efficacy.

In this study, the company explained that significant improvements in GVHD scores and survival rates were confirmed when HM15912 was administered as both preventive and therapeutic treatments in a GVHD animal model. Additionally, results showed that HM15912’s gastrointestinal protective and regenerative abilities positively affected gastrointestinal involvement, which is the main cause of death in GVHD.

In another study, HM15912 administration showed improvements in both GVHD scores and survival rates in a GVHD animal model that was unresponsive to steroids. Hanmi Pharmaceutical anticipates that this efficacy could provide a new treatment option for GVHD patients with steroid resistance.

A Hanmi Pharmaceutical representative stated, "Considering the great suffering experienced by patients and their families, the development of treatments for rare diseases is an area that pharmaceutical companies must pursue with a fundamental sense of mission until the end," adding, "We will do our best to contribute to the lives of rare disease patients through the development of innovative new drugs that present new treatment paradigms."

This content was produced with the assistance of AI translation services.